|
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis |
Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A, Avigdor A |
|
|
Record Status This is a systematic review that meets the criteria for inclusion on DARE. Bibliographic details Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A, Avigdor A. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. British Journal of Haematology 2014; 166(5): 702-710 Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Boronic Acids /administration & Bortezomib; Clinical Trials, Phase III as Topic; Cyclophosphamide /administration & Dexamethasone /administration & Humans; Induction Chemotherapy; Middle Aged; Multiple Myeloma /drug therapy /pathology; Pyrazines /administration & Randomized Controlled Trials as Topic; Remission Induction; Thalidomide /administration & dosage; dosage; dosage; dosage; dosage AccessionNumber 12014034723 Date bibliographic record published 02/10/2014 |
|
|
|